Cyclopharm (ASX:CYC) said that its Technegas technology, which provides high-resolution ventilation imaging at the site where oxygen is taken up in the lung, was approved for clinical use at the National Institutes of Health (NIH) in Bethesda, Maryland, according to a Wednesday Australian bourse filing.

The firm received a formal purchase order, and installation is expected in the coming weeks. The technology will be used for clinical ventilation imaging within NIH's protocol-driven clinical program.

The contract leverages the firm's five-year federal supply schedule agreement, which provides streamlined procurement access across US federal healthcare institutions.

Its shares rose 1% in recent trading on Wednesday.